Pipeline
ATA2271/ATA3271
ATA2271 and ATA3271: Mesothelin CAR T Programs in Solid Tumors
- Mesothelin is a target associated with aggressive solid tumors
- Expresses scFv that binds to mesothelin above cancer threshold
- Incorporates next-generation CAR T technologies combining novel 1XX costimulatory domain and PD-1 Dominant Negative Receptor (DNR)
- ATA3271: off-the-shelf, allogeneic EBV mesothelin CAR T
ATA2271/ATA3271
Autologous ATA2271 is in Phase 1 development and allogeneic ATA3271 is in preclinical development: both target solid tumors expressing the tumor antigen mesothelin and leverage novel next-generation 1XX co-stimulatory domain and PD-1 Dominant Negative Receptor technologies.
LEARN MORE- Program/Indication
- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
-
-
- Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
- MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
- ATA2271 Atara's CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
-
-
- Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Atara’s Next-Generation Solid Tumor CAR T cells
T and B-cell fractions are separated from a healthy donor via leukapheresis. The CD19+ fraction is transformed with EBV, generating an EBV+ lymphoblastoid cell line (BLCL). T cells are stimulated with BLCLs prior to retroviral introduction of mesothelin (MSLN)-targeted CAR with 1XX signaling domain and PD1DNR. The mesothelin scFv is derived from human anti-MSLN antibody m912. Continued expansion of MSLN-1XX-PD1DNR CAR+ EBV T cells (ATA3271) occurs with BLCL stimulation prior to harvest and cryopreservation for later use.
Next-Generation CAR T Technology
Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.